Abstract
A position paper by the European Network for Drug Allergy (ENDA), the European Academy of Allergology and Clinical Immunology (EAACI) interest group on drug hypersensitivity, defines drug provocation tests (DPTs) as ‘the controlled administration of a drug in order to diagnose drug hypersensitivity reactions’. The DPT is widely considered to be the ‘gold standard’ to establish or exclude the diagnosis of hypersensitivity to a certain substance, as it not only reproduces hypersensitivity symptoms, but also any other adverse clinical manifestation, irrespective of the mechanism. The DPT can be harmful and thus should only be considered after balancing the risk-benefit ratio in the individual patient. The ENDA position paper specifies two main indications for DPTs with the suspected compounds: 1. to exclude hypersensitivity in non-suggestive histories of drug hypersensitivity and in patients with non-specific symptoms, such as vagal symptoms under local anesthesia; 2. to establish a firm diagnosis in suggestive histories of drug hypersensitivity with negative, non-conclusive, or nonavailable allergologic tests. A positive DPT result optimizes allergen avoidance, while a negative one allows a false label of drug hypersensitivity to be removed. For these reasons, DPTs are often carried out to exclude a diagnosis of hypersensitivity to β-lactams when other allergologic tests are negative. DPTs are also performed when the sensitivity of allergologic tests for evaluating allergic reactions to certain drugs, such as non-β-lactam antibiotics, heparins, and glucocorticoids, is limited. On the other hand, DPTs are also performed to diagnose hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in subjects with the cross-reactive pattern, because both skin tests and in vitro diagnostic methods are ineffective in such patients.
Keywords: Challenges, diagnosis, drug allergy, hypersensitivity, provocation tests
Current Pharmaceutical Design
Title: Provocation Tests in Diagnosing Drug Hypersensitivity
Volume: 14 Issue: 27
Author(s): Philippe-Jean Bousquet, Francesco Gaeta, Laure Bousquet-Rouanet, Jean-Yves Lefrant, Pascal Demoly and Antonino Romano
Affiliation:
Keywords: Challenges, diagnosis, drug allergy, hypersensitivity, provocation tests
Abstract: A position paper by the European Network for Drug Allergy (ENDA), the European Academy of Allergology and Clinical Immunology (EAACI) interest group on drug hypersensitivity, defines drug provocation tests (DPTs) as ‘the controlled administration of a drug in order to diagnose drug hypersensitivity reactions’. The DPT is widely considered to be the ‘gold standard’ to establish or exclude the diagnosis of hypersensitivity to a certain substance, as it not only reproduces hypersensitivity symptoms, but also any other adverse clinical manifestation, irrespective of the mechanism. The DPT can be harmful and thus should only be considered after balancing the risk-benefit ratio in the individual patient. The ENDA position paper specifies two main indications for DPTs with the suspected compounds: 1. to exclude hypersensitivity in non-suggestive histories of drug hypersensitivity and in patients with non-specific symptoms, such as vagal symptoms under local anesthesia; 2. to establish a firm diagnosis in suggestive histories of drug hypersensitivity with negative, non-conclusive, or nonavailable allergologic tests. A positive DPT result optimizes allergen avoidance, while a negative one allows a false label of drug hypersensitivity to be removed. For these reasons, DPTs are often carried out to exclude a diagnosis of hypersensitivity to β-lactams when other allergologic tests are negative. DPTs are also performed when the sensitivity of allergologic tests for evaluating allergic reactions to certain drugs, such as non-β-lactam antibiotics, heparins, and glucocorticoids, is limited. On the other hand, DPTs are also performed to diagnose hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in subjects with the cross-reactive pattern, because both skin tests and in vitro diagnostic methods are ineffective in such patients.
Export Options
About this article
Cite this article as:
Bousquet Philippe-Jean, Gaeta Francesco, Bousquet-Rouanet Laure, Lefrant Jean-Yves, Demoly Pascal and Romano Antonino, Provocation Tests in Diagnosing Drug Hypersensitivity, Current Pharmaceutical Design 2008; 14 (27) . https://dx.doi.org/10.2174/138161208786369731
DOI https://dx.doi.org/10.2174/138161208786369731 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Interactions Effects of Cardiovascular Disorder Using Computational Models: A Review
Current Biotechnology Risk Factors of Alzheimers Disease Among Iranian Population
Current Alzheimer Research Antibiotic Susceptibility Evaluation of Bacterial Agents Causing Infection in Children with Acute Tonsillopharyngitis
Infectious Disorders - Drug Targets Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry Drug and Medical Device Interactions: Stent Thrombosis and Personalizing Clopidogrel Therapy
Current Pharmacogenomics and Personalized Medicine Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Evidence-Based Percutaneous Closure of the Left Atrial Appendage in Patients with Atrial Fibrillation
Current Cardiology Reviews Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures
Current Drug Targets N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology A Critical Review of Bioactive Food Components, and of their Functional Mechanisms, Biological Effects and Health Outcomes
Current Pharmaceutical Design Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Plant Sterols and Stanols as Cholesterol-Lowering Ingredients in Functional Foods
Recent Patents on Food, Nutrition & Agriculture Heart Failure in the Middle East
Current Cardiology Reviews Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Marine Collagen as a Source of Bioactive Molecules: A Review
The Natural Products Journal